Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

LNP-023 demonstrates efficacy, both as add-on and monotherapy, in patients with PNH

Sep. 3, 2020

Bristol-Myers Squibb reports phase I data for the antithrombotic milvexian

Sep. 2, 2020

First clinical data for TAFIa inhibitor S-62798 presented

Sep. 2, 2020

FDA clears IND for clinical development of OMS-906 for PNH

Sep. 1, 2020

Discovery of novel HIF-PHD2 inhibitors for the treatment of anemia

Sep. 1, 2020

Early clinical reports suggest utility of Aggrastat for COVID-19-related thrombotic complications

Aug. 25, 2020

BioMarin receives complete response letter from FDA for valoctocogene roxaparvovec

Aug. 20, 2020

PRC member affects blood formation during aging

Aug. 10, 2020

Keros completes dosing of planned cohorts in phase I study of KER-047

Aug. 6, 2020

Novel humanized platelet mouse model predicts efficacy of experimental antiplatelet drugs

Aug. 5, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity
BioWorld
After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.